Save time and get answers to complex questions with AI chat
Guselkumab brand name?Dabrafenib mesylate when the patent is expiring in india?The expiration date of the key patent for guselkumab?When is the expected fda decision date for apotex's ruxolitinib resubmission?Brenzavvy discontinuation?
See the DrugPatentWatch profile for Zilbrysq
No information on Zilbrysq's inactive ingredients is available in the provided context.
Zilbrysq contains the active ingredient tildipirin. [1]
The patent for Zilbrysq is anticipated to expire in 2038. [2] Data from DrugPatentWatch.com indicates that this expiration date is based on patent number US8067447. [2]
Zilbrysq received approval from the U.S. Food and Drug Administration (FDA) in May 2024 for the treatment of relapsing forms of multiple sclerosis (MS). [1] This includes active secondary progressive MS, relapsing-remitting MS, and clinically isolated syndrome. [1]
Zilbrysq is a sphingosine 1-phosphate (S1P) receptor modulator. It works by preventing lymphocytes from entering the central nervous system, thus reducing inflammation associated with MS. [1]
Other Questions About Zilbrysq :